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Aim: To evaluate the tolerability and toxicity of PCI in patients with NSCLC.
Background: Prophylactic cranial irradiation (PCI) is a standard treatment for patients with
small cell lung cancer. There are data showing a decreasing ratio of brain metastases after
PCI  for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far,
there is no evidence for increasing overall survival. The main concern in this setting is the
tolerance and toxicity of the treatment.
Materials and methods: From 1999 to 2007, 50 patients with NSCLC treated with radical intent
underwent PCI (30 Gy in 15 fractions). Mean follow-up was 2.8 years. The tolerability and
hematological toxicity were evaluated in all patients, a part of participants had done neu-
ropsychological tests, magnetic resonance imaging with 1H nuclear magnetic resonanceestosterone level
RS – 1H nuclear magnetic
esonance spectra
spectra, and estimation of pituitary function.
Results: During follow-up, 20 patients developed distant metastases, 4-brain metastases.
Fourteen (30%) patients had acute side effects: (headache, nausea, erythema of the skin).
The symptoms did not require treatment breaks. Six patients complained of late side effects
(vertigo, nausea, anxiety, lower extremity weakness, deterioration of hearing and olfactoryhyperesthesia). Hematological complications were not observed. Testosterone levels tended
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to decrease (p = 0.062). Visual-motor function deteriorated after treatment (p < 0.059). Perfor-
mance IQ decreased (p < 0.025) and the difference between performance IQ and verbal IQ
increased (p < 0.011). Degenerative periventricular vascular changes were observed in two
patients. Analysis of the spectroscopic data showed metabolic but reversible alterations
after PCI.
Conclusion: PCI in the current series was well tolerated and associated with a relatively low
toxicity.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.1.  Background
The high incidence of brain metastases in patients with lung
cancer has led to an increased interest in prophylactic cranial
irradiation (PCI). PCI is now a standard treatment for patients
with small cell lung cancer (SCLC). It decreases the incidence
of brain metastases (BM) and increases the 3-year survival rate
from 15% to 21% in limited-disease SCLC and from 13% to
27% at 1 year in extensive-disease SCLC.1,2 After treatment of
patients with non-small cell lung cancer (NSCLC), BM develop
in 18–54% of patients,3–5 and may develop as the ﬁrst sign
of dissemination in 15–40% of patients.3,4 The risk of BM is
particularly high after surgery and in long term survivors.6,7
Most studies on PCI in NSCLC report a decrease in the inci-
dence of BM without an effect on overall survival.3–5,8–10,6 After
PCI, BM are reported in 4–9% of patients.5,8,10,11 The phase
III RTOG 0214 study5 published in 2011 comparing PCI versus
observation in patients with advanced NSCLC demonstrated
a reduced probability of BM by a factor of 2.52. Many  patients
and physicians consider the decrease in the incidence of BM to
be a sufﬁcient reason for PCI because of the devastating inﬂu-
ence of CNS involvement on the patient’s and family’s quality
of life, but a widespread use of PCI is withheld mainly due to
concerns about the toxicity of the treatment.
2.  Aim
The purpose of the present study was to evaluate the tolera-
bility and toxicity of PCI in patients with NSCLC treated with
standard therapy.
3.  Materials  and  methods
From 1999 to 2007, 50 patients with NSCLC treated at MCS
Memorial Institute of Oncology in Gliwice with deﬁnitive
therapy were asked to undergo PCI during the ﬁnal phase
of standard treatment. The group was not homogeneous
and comprised both patients who  had undergone surgery
and patients who  had undergone deﬁnitive radiotherapy or
chemo-radiotherapy.
All the patients participating in the study fulﬁlled
the inclusion criteria: histologically proven NSCLC, deﬁni-
tive treatment, ECOG performance status 0–2, age 18–75
years, white blood cell count of at least 4 × 103, platelet
count of at least 150 × 103, no history of other malignanttumors, and informed consent provided. Exclusion criteria
included distant metastases, diseases potentially impair-
ing CNS tolerance for radiotherapy (uncontrolled diabetes,
demyelinating disease, paraneoplastic symptoms, and gen-
eralized atherosclerosis). The study was approved by the
institutional review board and conformed to the tenets of the
Declaration of Helsinki.
The sixth edition of the International Union Against Can-
cer (UICC) tumor-node-metastases classiﬁcation was used for
staging. Patient characteristics are shown in Table 1.
PCI was deﬁned as whole brain radiotherapy to total dose
of 30 Gy in 15 fractions, given daily 5 times per week, dur-
ing the last 3 weeks of radiotherapy or at least 2 weeks
after the end of adjuvant chemotherapy (in patients not
treated with radiotherapy). The minimum interval between
chemotherapy and PCI was 2 weeks. Three-dimensional com-
puted tomography-based radiotherapy planning was used in
all cases and treatment was delivered by 6 and/or 20 MV  pho-
tons. Patients were immobilized with thermoplastic masks.
Any complaints related to PCI during and after treatment
were recorded, as well as events of alopecia and time to hair
regrowth.
A full blood count was performed before and immediately
after PCI in all patients.
Steroids were used at the discretion of the physician.
Pituitary function was estimated by measuring serum
testosterone levels before and immediately after PCI, and dur-
ing follow-up in 10 male patients.
Neuropsychological tests: the Benton Visual Retention
Test (method A, BVRT) and Bender Visual Motor Gestalt
Test (BVMGT) – scored using the Pascal-Suttell method were
performed before and immediately after PCI (n = 32) and 6
months after PCI (n = 10). The Wechsler Adult Intelligence
Scale-Revised (WAIS-R) test was performed before (n = 32) and
6 months after the treatment (n = 10).
Brain magnetic resonance imaging (MRI) was performed:
before PCI (exam 1), up to 1 month after PCI (exam 2),
and 3 months after PCI (exam 3) in 10 patients. All mag-
netic resonance images were reviewed by one radiologist
(ŁZ). In patients who underwent MRI, forty-four in vivo 1H
nuclear magnetic resonance spectra (MRS) were acquired (in
the same scheme) with the whole-body MRI/MRS 2T sys-
tem operating at the proton resonance frequency of 81.3 MHz
(during MRI examination). For each patient, volumes of
interest of 1.5 cm × 1.5 cm × 1.5 cm were located in the left
frontal and occipital normal-appearing white matter (NAWM).
The absolute concentrations of the main brain metabolites:
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Table 1 – Patient characteristics.
Characteristics
Number of patients 50
Men/women 41/9
Age range (years)/mean age 38–73/56
Staging (6th UICC)
Tx/T1/T2/T3/T4 1/1/32/6/10
Nx/N1/N2/N3 1/11/36/2
Clinical stage: undetermined/II
B/III A/III B
1/6/29/14
Histology
NSCLC (NOS) 3
Squamous cell carcinoma 30
Adenocarcinoma 14
Large-cell neuroendocrine
carcinoma
3
Deﬁnitive surgery
Yes/no 4/46
Chemotherapy
Yes/no 37/13
Chemotherapy protocol
Cisplatin + Vinorelbin 30
Cisplatin + Etoposide 4
Cisplatin + Gemcitabine 3
Number of chemotherapy cycles
Range (mean) 1–6 (mean 2.4)
1–2 8
3–4 24
5–6 4
Type of treatment
Surgery + adjuvant chemother-
apy ± radiotherapy
3
Neoadjuvant chemother-
apy + surgery + radiotherapy
1
Radical radiotherapy 13
Chemoradiotherapy 33
Radiotherapy dose
Mean (range) 66 (44–72) Gy
N
t
(
o
f
w
C
L
t
K
s
d
m
a
W
statistically signiﬁcant. The statistical difference was found
in visual-motor function (assessed in Bender Visual-Motor
Gestalt Test) that deteriorated immediately after treatment
Table 2 – Mean value of hemoglobin, white blood cell
and platelet before and after PCI.
Mean value of Hemoglobin
(g/dl)
White blood
cells × 103
Platelet
× 103NSCLC – non-small cell lung cancer, NOS – not otherwise speciﬁed.
-acetylaspartate (NAA), choline (Cho), myoinositol (mI),
otal creatine (tCr), glucose (Glc), glutamine and glutamate
Glx), lactate (Lac), and lipids (Lip) were calculated as previ-
usly described.12 To compare the obtained results with data
rom the available literature, the metabolite concentrations
ere additionally presented as the following ratios: NAA/tCr,
ho/tCr, Cho/NAA, mI/tCr, Lac/NAA, Lip/NAA, Glc/tCr, Glx/tCr,
ac/tCr, Lip/tCr.
Mean follow-up was 2.8 years (calculated from the last
reatment day).
Statistics: Overall survival was estimated with the
aplan–Meier test.
The Friedman and Wilcoxon tests were applied for
tatistical analysis of neuropsychologic tests and clinical
ata.
For evaluation of the spectroscopic data, the absolute
etabolite concentrations and metabolite ratios were paired
ccording to the examination schedule and subjected to the
ilcoxon matched pair test: exam 1 vs. exam 2, exam 1therapy 1 9 ( 2 0 1 4 ) 361–368 363
vs. exam 3, and exam 2 vs. exam 3. Analyzes were per-
formed separately for frontal and occipital volumes of interest.
The correlations between the absolute metabolite ratios were
tested with Pearson product-moment method.
4.  Results
Median overall survival was 1.8 years (range 0.15–5.1). The 3-
year survival rate was 32%.
Twelve (40%) patients developed distant metastases, 4 (8%)
had BM.  In three patients (6%), BM appeared during the ﬁrst
2 years of follow-up, two patients had isolated BM,  and one
had local recurrence simultaneously with BM.  In the fourth
patient, cerebral involvement was simultaneous with bone
metastases and was diagnosed 4.8 years after treatment.
Determination of quality of life (QoL) in all patients based
on RTOG questionnaires was impossible due to logistical rea-
sons and thus, it was not included in the study protocol.
Instead, we asked patients to report the complaints during
PCI and on follow-up visits. They were also asked how their
well-being had changed after PCI.
During PCI, 14 (30%) patients had acute side effects: 10
headache, 2 nausea, and 2 erythema of the irradiated skin.
All of the symptoms were easily treated and did not cause any
breaks or cessation of the treatment.
After PCI, 6 (13%) patients complained of late side effects
(one or two of the following): 3 for vertigo, 1 for nausea, 2 for
anxiety, 1 for deterioration of hearing and olfactory hyperes-
thesia, and 1 for lower extremity weakness.
All patients developed alopecia after PCI. In all but one
patient, hair regrowth was observed between 1.5 and 6 months
after PCI (median 2.5 months).
There was no signiﬁcant change in blood count at the com-
pletion of PCI. White blood cell counts tended to increase at
the end of PCI. Conversely, platelet counts tended to decrease
but without statistical signiﬁcance (Table 2).
Serum testosterone levels declined during treatment and
during the ﬁrst months after treatment, but still the difference
did not reach statistical signiﬁcance (Wilcoxon test p = 0.062)
(Fig. 1).
In neuropsychological tests intelligence and visual mem-
ory (assessed in WAIS-R and BVRT) did not change between
subsequent examinations (before and after PCI). Before brain
irradiation 13% of patients demonstrated visual memory
impairment (adjusted to age and IQ). After the treatment
the percentage decreased to 9%, but the difference was notBefore PCI 12.8 8.2 275
After PCI 12.9 11.5 264
p value 0.6 0.21 0.5
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Table 3 – Results of neuropsychological tests.
Variable Before PCI (32 pts) After PCI (32 pts) 6 months after
PCI (10 pts)
p – Friedman
Anova
IQ (WAIS-R)
Mean points (SD)
97.1 (SD = 16.5) – 94.9 (SD = 22.5) p = 0.31
Verbal IQ (VIQ)
Mean points (SD)
100.53 (SD = 14.8) – 101.2 (SD = 20) p = 0.09
Performance IQ (PIQ)
Mean points (SD)
95.4 (SD = 14.6) – 90.6 (SD = 18.4) p = 0.02
Difference between PIQ and
VIQ ()
Mean points (SD)
3.9 (SD = 12.4) – 10.6 (SD = 12.4) p = 0.011
Benton Visual Retention
Test (BVRT)
Mean number of correct
answers (SD)
6.4  (SD = 2) 6.4 (SD = 2.6) 6.2 (SD = 2.6) p = 0.89
BVRT No of errors
Mean (SD)
5.4  (SD = 3.3) 5 (SD = 3.9) 4.8 (SD = 3.9) p = 0.60
BVRT – Cognitive function
damage adjusted to age
and IQ – percentage of
patients with damage
13%  9% 0 p = 0.51
BVMGT Bender
Visual-Motor Gestalt
Testa
Mean points (SD)
88.3 (SD = 20.5) 92.9 (SD = 26) 101.6 (SD = 19.4) p = 0.40
Wilcoxon test before and after PCI – p = 0.059
BVMGT Visual-motor
function damage
adjusted to age and
education – percentage of
patients with damage
31%  41% 67% p = 0.44
s (the
SD – standard deviation.
a In BVMGT normal score for Polish population is less than 100 point
(Wilcoxon test p < 0.05), but after 6 months the difference was
no longer statistically signiﬁcant. Performance IQ slightly but
signiﬁcantly decreased by 5 points 6 months after PCI (p < 0.02).
Similarly, the difference between performance IQ and ver-
bal IQ increased 6 months after treatment (p < 0.011), which
could suggest a slight psychoorganic cognitive deterioration
(Table 3).
Fig. 1 – Testosterone serum level before and after treatment. less points is for the better results).
In MRI, degenerative periventricular vascular changes were
observed in 2/10 patients.
The analysis of spectroscopic data showed no statisti-
cally signiﬁcant differences in the occipital normal-appearing
white matter (NAWM) between examinations, while in
the frontal NAWM statistically signiﬁcant differences were
observed only between exam 1 (before PCI) and exam 2
(up to 30 days post PCI) in both the absolute metabo-
lite concentrations and their ratios. These differences were
detected by Wilcoxon matched pair test in tCr (p = 0.0277),
Lac (p = 0.018), and Glc (p = 0.0464) as well as in Lac/NAA
(p = 0.028), Lac/tCr (p = 0.018), and Lip/tCr (p = 0.0425) (Table 4).
Moreover, statistically signiﬁcant inverse correlations in sub-
sequent examinations were found between Lac and Glc in the
frontal NAWM (r = −0.44, p = 0.038, Fig. 2).
5.  Discussion
In oncology, radiotherapy of regions potentially harboring
micrometastases has got a well established role in treat-
ment of many  types of cancer. Particularly well examined and
widely used is the positive effect of elective radiotherapy in
nodal regions in patients with squamous-cell cancer of the
head and neck. A total dose of 50 Gy in 2 Gy fractions reduces
nodal recurrences by 60%.13 Assuming similar radiosensitivity
of brain micrometastases from NSCLC, it can be theoretically
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Table 4 – Results of the analysis of spectroscopic data.
Before PCI Up to 30 days More  than 90 days
Absolute metabolite concentrations median (min–max). Valid cases 7
tCr 3.2 (1.35–5.2) 1.75 (1.0–3.09) 2.51 (1.25–3.09)
p = 0.023
Lac 1.1 (0.2–4.13) 3.2 (1.2–7.9) 2.95 (1.1–6.2)
p = 0.018
Glc 1.45 (0.44–2.39) 0.79 (0.4–1.81) 1.0 (0.3–1.39)
p = 0.046
Metabolite ratios median (min–max). Valid cases 7
Lac/NAA 0.4 (0.09–2.69) 2.1 (0.4–5.0) 2 (0.4–2.9)
p = 0.028
Lac/tCr 0.49 (0.1–2.07) 0.48 (1.2–7.95) 1.2 (0.5–3.9)
p = 0.018
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BLip/tCr 3 (2–11.5) 
p = 0.042
stimated that the incidence of BM after PCI with a dose
f 30 Gy would be reduced by 20–30%.13 The high probabil-
ty of developing BM in patients with NSCLC (up to 58%) has
aised the question about the effectiveness of PCI. The RTOG
214 study comparing PCI versus observation in patients with
dvanced NSCL demonstrated a reduced probability of BM by
 factor of 2.52 after elective treatment, which is higher than
redicted based on theoretical calculations.5 Data from earlier
tudies on PCI in SCLC have indicated deterioration of cogni-
ive function after PCI (mainly in cases of concomitant use of
CI and chemotherapy) raising doubts about safety of PCI.14,15
The RTOG 0214 study5 was closed prematurely due to slow
ccrual, reﬂecting the uncertainly and anxiety of patients and
hysicians regarding the potential toxicity of brain irradiation.
hole brain irradiation was the standard treatment for BM
or many  years16 with an estimated response rate for BM after
hole brain irradiation of 60%.17 The paucity of data on acute
nd especially late toxicity after whole brain irradiation for
M is likely due to the short survival of patients with NSCLC.
Fig. 2 – Correlation between Lac and Glc absolute concent16.1 (3–23) 9.8 (6–25.5)
Data on toxicity after PCI in SCLC are focused mainly on the
neuropsychological changes.
The toxicity of PCI in the current series was mild and mostly
self-limiting. We  did not observe signiﬁcant decline in blood
count at the end of PCI. It is important to note that inclusion
criteria required enrollment of patients without signiﬁcant
hematological toxicity after chemotherapy. Surprisingly, in the
available literature (according to our best knowledge), there
are no data on hematologic tolerance of WBRT.  The present
ﬁndings demonstrated good hematologic tolerance of PCI.
Only slight and statistically not signiﬁcant decrease in platelet
count was noted. White blood cells count even increased at the
end of treatment. It may be explained by the use of steroids in
some patients.
Although 30% of the patients experienced acute toxicity:
headache, nausea, or erythema of the irradiated skin, the
symptoms did not present a serious problem, and were quickly
and successfully relieved by standard pharmacologic treat-
ments (steroids and non-steroids).
ration in the frontal normal-appearing white matter.
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The late toxicity is the main concern of the treatment. In
the presented study vertigo was the most common late side
effect (6%) which may be related to irradiation of the inner ear
during the course of PCI. It cannot be excluded, however, that
the late symptoms were caused by the disease itself, paraneo-
plastic syndromes, late effects of chemotherapy, or prolonged
stress. It is important to note that the severity of the symptoms
was low and the patients did not consider them noticeably
detrimental to their quality of life.
Alopecia after PCI was transient with median time to hair
regrowth of 2.5 months. One patient died 2 months after treat-
ment, before the hair regrowth, because of dissemination to
the lung. It is worth mentioning that fear of alopecia was the
most frequently given reason for not participating in the study.
Endocrine changes are the least of all evaluated alterations
after PCI and whole brain irradiation. For the sake of simplic-
ity, we  chose testosterone level as the most direct indicator
of pituitary dysfunction. Testosterone is the feedback hor-
mone for luteinizing hormone (LH) and follicle-stimulating
hormone (FSH), so the decline in LH/FSH level after pituitary
irradiation will cause proportional decline in testosterone
level. Other hormones, as estradiol or thyroid hormone, are
much more  dependent on other factors, like menstrual cycle
or iodine contrast used for computed tomography. Although
our analysis included only 10 male patients, to the best of
our knowledge, this study represents the ﬁrst estimation of
endocrine changes after PCI in the literature. In the current
analysis a non-signiﬁcant decline in the serum testosterone
levels after PCI was observed. Fatigue is the most common
adverse effect reported by patients with SCLC after PCI.18 In
older men, a decline in testosterone levels is associated with
fatigue and deterioration of cognitive function,19,20 and the
same effect might be caused by endocrine changes after PCI.
Simple supplementation with testosterone could possibly be
beneﬁcial for those patients.
To the best of our knowledge, spectroscopic analysis before
and after PCI has not been previously reported. The observed
elevation in the Lac concentration as well as the Lac/NAA
and Lac/tCr ratios were most prominent within 30 days after
irradiation. This phenomenon could be explained by radi-
ation damage leading to impaired lactate washout due to
post-irradiation edema, an increased lactate concentration
caused by radiation-induced cell-kill, or by disturbed glu-
cose metabolism.21,22 The decreased glucose concentration
in the early period after PCI coinciding with the elevation
of lactate level and the reverse tendency later suggest that
the last mechanism may play a signiﬁcant role in this phe-
nomenon. The decrease of glucose concentration can be
caused both by its increased consumption due to repair pro-
cesses in neural and glial cells or by impaired delivery caused
by radiation-induced edema. The exact reason of the observed
inverse correlation between glucose and lactate concentra-
tions in the frontal NAWM in all time-points is unclear but
this observation can be a groundwork for further studies.
Similarly, an increase in the Lip/tCr ratio could be explained
by cell membrane disintegration due to ionization. Both
Lac/tCr and Lip/tCr ratios reached the highest level imme-
diately after irradiation (<30 days) and varied widely among
individual patients. Whether the observed alterations are
solely the effect of irradiation or the previous treatment likeiotherapy 1 9 ( 2 0 1 4 ) 361–368
chemotherapy inﬂuenced the results is not known. The most
prominent alterations were, however, observed immediately
after irradiation as compared to the spectra acquired before
PCI which suggests that the damaging action of ionizing radi-
ation played the main role here.
White matter changes seen in radiological imagining after
whole brain radiotherapy, deﬁned as hyperintensity from focal
to conﬂuent, are reported in 38–50% patients.23 These changes
are usually asymptomatic, and discovered only by imaging
studies.23,24 Changes after PCI observed in the present study
were moderate and reﬂected demyelination in the periventric-
ular region with no clinical relevance.
Precise neuropsychologic tests performed during the RTOG
0214 study showed no signiﬁcant differences in global cog-
nitive function or QOL after PCI, but there was a signiﬁcant
decline in memory  at 1 year after treatment.25 In the present
study, neuropsychologic tests revealed a slight decrease
in cognitive function (in WAIS-R examination) 6 months
after treatment. The patients themselves did not complain
about deterioration of cognitive functions, consequently, the
observed decline can be considered clinically irrelevant and
not inﬂuencing the patients’ quality of life.
In SCLC patients there were attempts to decrease the dete-
riorative effects of PCI on cognitive function by using speciﬁc
techniques of irradiation (intensity-modulated radiotherapy,
helical TomoTherapy, and Rapid Arc) allowing to spare neural
stem cells (found mainly in hippocampus).26,27 Similar tech-
niques may be used in NSCLC patients. Possibly sparing the
pituitary gland and the inner ears from high dose of irradia-
tion may also be beneﬁcial for this group of patients, hopefully
by alleviation of the hormonal changes after PCI and possibly
also vertigo.
To date, clinical trials have not demonstrated positive effect
of PCI on overall survival, the reasons for that are complex. The
reduction in the incidence of BM stated in almost all papers
on PCI conﬁrm the radiosensitivity of cerebral micrometas-
tases. Consequently, PCI could possibly increase survival in
patients who are at high risk of death from metastases to the
brain. The cause of death in NSCLC (also in case of patients
after PCI) is mainly dissemination to other sites or (rarely)
locoregional progression. Thus, patients with a high probabil-
ity of brain dissemination and a low probability of non-central
nervous system (CNS) dissemination are probably more  likely
to achieve a survival gain from PCI. According to Gaspar
et al., isolated brain metastases occur in 11% of patients and
this subgroup should gain maximum beneﬁt from PCI.28 This
assumption is conﬁrmed by data showing beneﬁts for patients
with isolated brain metastases from NSCLC when chemo-
irradiation of the primary tumor and WBRT  is applied unless
there are no excessive lymph node metastases.29
Currently there are no good tools to select such patients.
Consequently, the aim of future studies should be to deter-
mine the subset of patients with a high probability of BM,
a high probability of locoregional cure, and low risk of dis-
tant non-CNS metastases. Still, the reduced probability of BM
could be beneﬁcial even for patients with dissemination to
other sites (which proved to be true for patients with SCLC),
but for this group of patients a close follow-up with brain
imaging studies for occult metastases may be a reasonable
option.
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.  Conclusions
rophylactic cranial irradiation can be safely performed in
SCLC patients with relatively low impact on their cognitive
tatus and self-assessed well-being. The decrease of blood
estosterone level can be suggestive of pituitary dysfunction
nd requires further studies, especially in patients subject
o WBRT  with relatively good prognosis and anticipated
ong-term survival. WBRT  alters prominently the cerebral
etabolism in the early period after irradiation which may
ontribute to mechanisms underlying the observed acute tox-
city symptoms. The metabolic alterations triggered by PCI
eem temporal and tended to reverse but more  detailed stud-
es are needed to gain deeper insight into the metabolism of
he brain subject to irradiation in the particular clinical setting.
To alleviate side effects and to further increase the toler-
nce of PCI, specialized techniques of irradiation sparing the
nner ear, pituitary gland and hippocampus should be consid-
red.
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